Table 16IMRT vs. 3DCRT: Summary data on mixed settings for mixed tumor sites

StudySettingOutcomenUnivariate p valueMultivariable p valueStudy designInitial groups comparable?Treatments in same time period?Well-done multivariable analysis?Study quality rating
Vergeer et al. 2008[34]Primary/postoperative RT ± concurrent chemotherapyQuality of life1411.5/6 mo EORTC QLQ-C30, ANOVA with linear (l) and quadratic (q, changing effect sizes over time) time analyses
Domains with statistically significant results: Global Health <.004-l, Role Function .042-l, Cognitive Function .033-l, Social Function <.001-l, Fatigue .026-l, Pain .042-q, Insomnia <.021-l, Appetite Loss .018-l
Domains with NS results: Physical Function, Emotional Function, Nausea/Vomiting, Dyspnea, Constipation, Diarrhea, Financial Difficulties 1.5/6 mo EORTC QLQ-H&N35
Domains with statistically significant results: Pain .03-l, .046- q; Swallowing .042-l, Social Eating .011-l, Sexuality .003-l, Teeth .015-l, Opening Mouth .026-q, Dry Mouth <.001-l, Sticky Saliva .001-l, Feeling Ill .0011-l Domains with NS results: Taste/Smell, Speech, Coughing
ProspectiveNoNoNot donePoor
Marchal et al. 2004[79]Primary/postoperative/repeat RT ± pre-RT/post-RT/concurrent chemotherapyXerostomia87Acute, ≥ Gr 2, Δ−1, p NR Late, ≥ Gr 2, Δ−8, .06ProspectiveUnclearYesNot donePoor
Palazzi et al. 2008[80]Primary/postoperative RT ± concurrent ± pre-RT chemotherapyXerostomia137Acute, > Gr 2NSProspectiveUnclearNoUnclearPoor
Vergeer et al. 2008[34]Xerostomia141Acute, Gr 2, Δ−17, .014
Late, Gr mod-sev, Δ−26, ≤ .001
Late mean xerostomia item from EORTC QLQ- H&N35, at 1.5/6/12 mo IMRT- ≤ .002
Late, ≥ Gr 2, IMRT- .002
mod-sev, MV logistic regression adjusted OR (95% CI): 0.27 (0.13, 0.54) Gr 2–3, MV logistic regression adjusted OR (95% CI): 0.24 (0.12, 0.51)Unclear
Chao et al. 2001[65]Primary/postoperative RT ± post-RT/concurrent chemotherapySalivary flow416 mos., stimulated whole salivary flowNSProspectiveUnclearYesUnclearPoor
Palazzi et al. 2008[80]Dysphagia137Acute, > Gr 2NS
Langendijk et al. 2009[89]Primary/postoperative RT± chemotherapy with unclear timingDysphagia529Late, Gr 2–4, Δ+12, .043Not reportedProspectiveUnclearYesNoPoor
Palazzi et al. 2008[80]Mucositis137Acute, > Gr 2NS
Vergeer et al. 2008[34]Mucositis141Acute, ≥ Gr 3, Δ−4 NS
Palazzi et al. 2008[80]Skin toxicity137Acute, > Gr 2NS
Vergeer et al. 2008[34]Skin toxicity141Acute, Gr 2, Δ+12, .03
Marchal et al. 2004[79]Disease- free survival871 yr., Δ+3, NS
Gomez et al. 2008[70]Primary/postoperative RT ± chemotherapy with unclear timingDisease- free survival42NSNot enteredRetrospectiveUnclearYesUnclearPoor
Marchal et al. 2004[79]Overall survival871 yr., Δ+3, NS
Gomez et al. 2008[70]Overall survival42NSNot entered

Abbreviations: Δ: change; Gr: grade; mos.: months; NR: not reported; NS: not significant; RT: radiotherapy; yr: year;

From: Results

Cover of Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet].
Comparative Effectiveness Reviews, No. 20.
Samson DJ, Ratko TA, Rothenberg BM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.